Phaseline

Targets › MAGE-A4

MAGE-A4: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on MAGE-A4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Immatics BiotechnologiesIMA401
TCER® (T cell engineered receptor) targeting MAGE-A4 and/or MAGE-A8
MAGE-A4, MAGE-A8Phase 1Refractory CancerSep 2027
USWM CTAutologous genetically modified MAGE-A4ᶜ¹º³²T cells
T cell receptor (TCR) engineered T cells targeting MAGE-A4
MAGE-A4Phase 1Urinary Bladder CancerSep 2032

Conditions

Refractory Cancer (2) Urinary Bladder Cancer (1)

Modalities

other (1), mixed (1)

Companies

USWM CT (1) Immatics Biotechnologies (1)

Related targets

MAGE-A8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.